Private Markets

BioSculpture Technology, Inc.

Corporate Capsule

BioSculpture Technology, Inc. has a qualifed tier 2 Regulation A Offering to commercialize its patented minimally invasive EVL® device and method for the endoscopic removal of visceral or “belly” fat, as a new treatment of obesity, metabolic syndrome and type 2 Diabetes mellitus. Scientific research has confirmed that excessive visceral fat within the abdominal cavity causes metabolic syndrome and type 2 diabetes, decreasing the quality of human life and shortening the lives of those we love.

We believe our patented technology and surgical procedure, Endoscopic Visceral Lipectomy (“EVL”), illustrated in this short medical video, will save and improve millions of human lives each year, while significantly reducing healthcare costs. While safety and efficacy studies are yet to be performed and regulatory approvals obtained, the Company believes an EVL procedure may not only replace Lap-band® but will do for obesity treatment what LASER eye surgery has done for vision correction.

Medical Movie

The medical movie provides a brief description and depiction of a proposed Endoscopic Visceral Lipectomy or an " EVL" procedure carried out with BioSculpture Technology, Inc.'s patented method and EVL(R) device to remove the visceral or "belly" fat which causes $2 Trillion dollars of yearly obesity-related diseases including, gastric reflux, sleep apnea, hypertension, cancers and autoimmune diseases, and most importantly type 2 Diabetes mellitus.

Please note Endoscopic Visceral Lipectomy has not yet been proven safe and effective and the EVL® device has not yet received regulatory approvals.

Learn More

Emerging Growth

Kiwa Bio-Tech Products Group Corp

Kiwa Bio-Tech Products Group Corp develops, manufactures, distributes and markets, cost-effective and environmentally safe bio-technological products for agriculture in China.